ACETAMINOPHEN AND IBUPROFEN

Post-LOE

acetaminophen 250 mg and ibuprofen 125 mg tablets

Taro

ANDAORALTABLET

Approved

Jan 2026

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ACETAMINOPHEN AND IBUPROFEN (acetaminophen 250 mg and ibuprofen 125 mg tablets) by Taro is cyclooxygenase inhibitors [moa]. Approved for moderate to severe pain, less. First approved in 2026.

Drug data last refreshed 2h ago

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (2)

moderate to severe pain less

Worked on ACETAMINOPHEN AND IBUPROFEN at Taro? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.